Droplet Digital PCR (ddPCR)

In June, Bio-Rad hosted Droplet Digital PCR (ddPCR) World 2024, the premier digital PCR event bringing together global leaders in science and innovation. ddPCR World features experts showcasing how ddPCR technology has been instrumental in overcoming some of their most complex research and manufacturing challenges. In this article, we are excited to share key insights and cutting-edge research using ddPCR technology that are driving scientific breakthroughs across the globe.

Estrogen receptor 1 (ESR1) mutations in breast tumors were first identified nearly 30 years ago. Since then, technology has evolved, as has our understanding of the impact these mutations have on tumor cell physiology. Given the dynamic nature of ESR1 mutation acquisition and enrichment, ctDNA samples appear to be the most robust source for analysis. Droplet Digital PCR (ddPCR) enables rapid, highly sensitive, cost-effective analysis of ctDNA, providing a powerful tool for this critical area of cancer research.

A common challenge in scaling up cell and gene therapy production is monitoring for contaminants, such as Mycoplasma. Learn how ddPCR can help in this webinar.

In this webinar, learn about validating qPCR and ddPCR assays in regulated environments. Explore validation parameters and regulatory considerations.

Scientists commonly use lentiviruses and adeno-associated viruses (AAVs) as viral vectors in cell and gene therapy (CGT) production. However, therapies that use these viruses must undergo strict quality control measures, including testing for replication-competent viruses (RCV), to ensure that the treatment is safe. Cell culture-based methods are currently the gold standard for RCV testing, but it can take up to 45 days for results to be returned. Droplet Digital PCR (ddPCR) kits now offer an attractive orthogonal method.

As the third most prevalent cancer worldwide, colorectal cancer (CRC) is a significant global health burden. Biomarker identification and detection has proven a powerful strategy for improving CRC diagnosis and informing targeted treatment. Microsatellite instability (MSI) is a key biomarker in CRC, and with Droplet Digital PCR (ddPCR), MSI can be accurately detected using a wider range of sample types.

The therapeutic potential of messenger RNA (mRNA) therapeutics has an unprecedented ability to target previously undruggable diseases. The poly(A) tail drives the therapeutic efficacy of the mRNA molecule. Using Droplet Digital PCR (ddPCR) technology to analyze poly(A) tail length and integrity yields unrivaled sensitivity, enabling developers to ensure high poly(A) tail integrity and, ultimately, functional therapeutic mRNAs.

Lentiviral vectors (LVVs) have become the primary method of gene delivery for cells ex vivo in both academic and clinical applications. Currently, qPCR is the gold standard for functional titering of LVVs, but Droplet Digital PCR (ddPCR) offers an attractive alternative due to its inherent benefits, such as absolute quantification without the use of a standard curve and enhanced resistance to PCR inhibitors.

The realm of druggable targets has expanded significantly with the advent of mRNA therapeutics. Scientists require exceptional accuracy and confidence to adequately characterize these therapeutics and their anticipated effects. To this end, Droplet Digital PCR (ddPCR) technology has proven invaluable. With unparalleled precision and absolute quantification, Droplet Digital PCR is revolutionizing the field of mRNA therapeutic development and manufacturing.

Historically, five-year survival rates have been used to evaluate cancer therapeutic effectiveness in clinical trials. But time is critical for research — and for patients. Fortunately, there is a promising method for evaluating cancer therapeutic effectiveness that could potentially offer prognostic insights after just one year. Noninvasive liquid biopsy analysis, including analysis of circulating tumor DNA, is improving researchers’ ability to detect clinical responses more rapidly.